eIFs as novel biomarkers in bladder cancer
Kurzbeschreibung
With the novel biomarkers of the present invention, a clinical diagnosis, as well as the course determination of bladder cancer can be derived. The biomarkers show differences between affected patients and healthy individuals.
Beschreibung/Hintergrund
Bladder cancer is the second most common genitourinary malignancy and represents the 9th most common cancer worldwide. Urinary bladder cancer (UBC) is the most common histology of the bladder cancer and is associated with high mortality rates and poor prognosis. Painless hematuria and other signs and symptoms of UBC are not specific and often arise at late stage of disease. Thus, diagnosis is typically made when the cancer is already in advanced stages and prognosis for survival is bad.
Lösung
Bladder cancer is the second most common genitourinary malignancy and represents the 9th most common cancer worldwide. Urinary bladder cancer (UBC) is the most common histology of the bladder cancer and is associated with high mortality rates and poor prognosis. Painless hematuria and other signs and symptoms of UBC are not specific and often arise at late stage of disease. Thus, diagnosis is typically made when the cancer is already in advanced stages and prognosis for survival is bad.